Melanie A. Leiby

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

A New Positive/Negative Selection Scheme for Precise BAC Recombineering

Shuwen Wang, Yuanjun Zhao, Melanie A. Leiby et al. · Molecular Biotechnology · 2009 · 105 citations

Medicine, Biotechnology, Molecular Genetics +11

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.

Julie R. Brahmer, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2017 · 53 citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.

Aurélien Marabelle, Philippe A. Cassier, Marwan Fakih et al. · Journal of Clinical Oncology · 2020 · 28 citations

Medicine, Oncology, Pharmacotherapy +16

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Annals of Oncology · 2016 · 17 citations · Full text

Medicine, Oncology, Pharmacology +12